Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 8/20 | 0.65 |
| ▸ | RAB9A | P51151 | 8/20 | 0.64 |
| ▸ | MAPT | P10636 | 6/20 | 0.60 |
| ▸ | MEN1 | O00255 | 6/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.60 |
| ▸ | LMNA | P02545 | 3/20 | 0.60 |
| ▸ | HTT | P42858 | 3/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.60 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.60 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.60 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.56 |
| ▸ | PKM | P14618 | 2/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.54 |
| ▸ | GAA | P10253 | 4/20 | 0.53 |
| ▸ | TP53 | P04637 | 1/20 | 0.52 |
| ▸ | TNF | P01375 | 2/20 | 0.51 |
| ▸ | NOD2 | Q9HC29 | 2/20 | 0.51 |
| ▸ | NOD1 | Q9Y239 | 2/20 | 0.51 |
| ▸ | CRHBP | P24387 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3792415 | 0.82 | RAB9A (0.70) | NPC1RAB9AMAPTMEN1KMT2A | |
| SCHEMBL3044982 | 0.81 | RAB9A (0.68) | NPC1RAB9AMAPTMEN1KMT2A | |
| SCHEMBL31504583 | 0.81 | RAB9A (0.64) | NPC1RAB9AMAPTMEN1KMT2A | |
| SCHEMBL27004512 | 0.81 | RAB9A (0.64) | NPC1RAB9AMAPTMEN1KMT2A | |
| SCHEMBL11268232 | 0.78 | NPC1 (0.53) | NPC1RAB9AMAPTALDH1A1LMNA | |
| SCHEMBL17251987 | 0.78 | PDPK1 (0.68) | NPC1RAB9AMAPTMEN1KMT2A | |
| SCHEMBL4921505 | 0.77 | NPC1 (0.62) | NPC1RAB9AMAPTMEN1KMT2A | |
| SCHEMBL3049281 | 0.76 | LMNA (0.77) | NPC1RAB9AMAPTMEN1KMT2A | |
| SCHEMBL16919783 | 0.76 | RAB9A (1.00) | NPC1RAB9AMAPTMEN1KMT2A | |
| SCHEMBL27004472 | 0.75 | RAB9A (0.56) | NPC1RAB9AMAPTMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12247029-B2 | Heterocyclic compounds as class II phosphoinositide 3-kinase inhibitors | FORSCHUNGSVERBUND BERLIN E.V. (DE) | 2025-03-11 | — | — | US | disclosed |
| EP-3802530-B1 | HETEROCYCLIC COMPOUNDS AS CLASS II PHOSPHOINOSITIDE 3-KINASE INHIBITORS | FORSCHUNGSVERBUND BERLIN EV (DE) | 2024-05-29 | — | — | EP | disclosed |
| US-20220332717-A1 | HETEROCYCLIC COMPOUNDS AS CLASS II PHOSPHOINOSITIDE 3-KINASE INHIBITORS | FORSCHUNGSVERBUND BERLIN E.V. (DE) | 2022-10-20 | — | — | US | disclosed |
| WO-2019234237-A1 | HETEROCYCLIC COMPOUNDS AS CLASS II PHOSPHOINOSITIDE 3-KINASE INHIBITORS | FORSCHUNGSVERBUND BERLIN E.V. (DE) | 2019-12-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12247029-B2 | Heterocyclic compounds as class II phosphoinositide 3-kinase inhibitors | PIK3CA, PIK3CD, PIK3C2B | NPC1 3757/4885RAB9A 1085/4885MAPT 4587/4885 |
| US-20220332717-A1 | HETEROCYCLIC COMPOUNDS AS CLASS II PHOSPHOINOSITIDE 3-KINASE INHIBITORS | PIK3CA, PIK3CD, PIK3C2B | NPC1 3757/4885RAB9A 1085/4885MAPT 4587/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.